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In the formation of specific 
inflammation with subsequent 
extravasation of inflammatory 
reaction cells and their accumulation 
in tissues, it is controlled by specific 
immunity mediators - cytokines. 
Evaluation of the pro- and anti-
inflammatory profile of cytokines 
allows obtaining information on the 
functional activity of various types 
of immunocompetent cells and the 
degree of activation of T-helpers, 
the expressiveness of the types of 
the inflammatory process and its 
prognosis, as well as monitoring the 
effectiveness of the therapy.
Coronavirus and tuberculosis, 
although caused by various 
pathogens, have many common 
features. In the pathogenesis of 
COVID-19 and tuberculosis is the 
same features, a hyper-inflammatory 
reaction of the body, characterized 
by a pathological level of cytokines, is 
common. Work by Ruan et al. shows 
that the critically ill with COVID-19 
admitted to the ICU had higher 
systemic levels of IL-2, IL-7, IL-10, 
granulocyte-colony-stimulating 
factor, monocyte chemoattractant 
protein-1 (MCP-1), macrophage 
inflammatory protein-1A (MIP-
1A) and tumour necrosis factor-α 
(TNF-α). Moreover, Diao et al. found 
that the levels of TNF-α, IL-6 and IL-
10 were correlated with the severity 
of COVID-19.
Interleukin 6 (IL-6) is an 
interleukin that affects the activity 
of various types of cells. IL-6 is 
considered to be one of the most 
important cytokines during an 
infection because it controls the 
differentiation of monocytes into 
macrophages, increases B-cell IgG 
production. It is important that the 
release of IL-6 in the inflammatory 
environment occurs for a huge 
number of cells that secrete it, which 
are structural components of the 
infected tissue and not necessarily 
part of the immune system as 
such, that is, mesenchymal cells, 
endothelial cells, fibroblasts and 
others are involved in the production 
of IL-6. Functionally, IL-6 enters the 
liver through the bloodstream and 
rapidly activates hepatocytes to form 
C-reactive proteins, serum amyloid 
A, and promotes the release of 
fibrinogen. Centrally, IL-6 promotes 
the differentiation of naïve CD4 T 
cells into effector and helper cells. 
 On a side note, some viruses 
and bacteria can manipulate the 
intracellular cascade of events 
attributing to the inflammatory status 
and the release of IL-6. An example 
of this is tuberculosis. Our research 
results showed that the level of 
IL-6 in the blood of patients with 
tuberculosis significantly increased 
by 11.08 times, with resistance 
tuberculosis – by 13.9 times. The 
probable increase in the content of 
IL-6 in the blood plasma indicates 
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a high activity of the systemic 
inflammatory reaction, which is 
most pronounced in multi-resistant 
tuberculosis (23.70 ± 13.39 pg/ml). 
This cytokine plays a major role in 
the development of the inflammatory 
process, the immune response to 
an infectious factor and damage to 
the lung tissue with the formation 
of massive destructive changes. 
IL-6 is assigned a special role as 
a “hepatocyte-activating factor”, 
which promotes the induction of 
the synthesis of many acute-phase 
proteins of the general inflammatory 
response, which leads to the release 
of specific inflammation outside 
the bronchopulmonary tissue 
and activation of the “systemic 
inflammatory response” syndrome. It 
has been proven that in tuberculosis 
and COVID-19, an increased level 
of IL-6 (next to TNF-α and IL10) 
is significantly associated with a 
decrease in the chances of recovery 
and the need for intensive care.
In summary, cytokines have an-
tigen-specific and antigen-indepen-
dent immune activation. In connec-
tion with the strengthening produc-
tion of IL-6 in pathogenesis these two 
diseases, builds the ground for the 
hypothesis that the two members of 
the different diseases might indeed 
share common physiopathological 
mechanisms. Elevated systemic IL-6 
levels according to disease severity 
should be important for determina-
tion of higher risk of disease dete-
rioration. Monitoring of the IL-6 or 
targeting treatment may be a new 
target for effective treatment.
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Атопічна екзема – це мульти-
факторне генетично детерміно-
ване хронічне запальне захворю-
вання шкіри, що характеризується 
свербіжем, рецидивуючим перебі-
гом і поліморфним висипом.
Ціль дослідження – персоні-
фікований підхід діагностики з ви-
користанням багатокомпонентно-
го колориметричного тесту ALEX2 
та ImmunoCAP і, таким чином, 
оптимізація лікування атопічної ек-
земи з використанням можливос-
тей АСІТ.
Матеріали та методи. Хвора 
А., 21 рік, з дитинства страждає на 
атопічну екзему із загостренням 
протягом останнього року. Осно-
вні симптоми – виразний свер-
біж, особливо вночі, поліморфний 
висип по всьому тілу, множинні 
осередки ліхеніфікації. SCORAD 
– 60,9 балів. Лікувалася протя-
гом тривалого часу у дерматоло-
га – без ефекту. Хвора пройшла 
повний курс обстеження та ліку-
вання згідно з європейськими ре-
комендаціями щодо лікування ато-
пічної екземи. Був проведен курс 
лікування циклоспорином у дозі 
